Vertex Pharmaceuticals Inc (VRTX) 65.05 $VRTX
Healthcare Companies Report Studies, Financial Results, and Upcoming Conferences - Analyst Notes on Vertex, PerkinElmer, PAREXEL, ACADIA Pharmaceuticals and Arena Pharmaceuticals
PR Newswire - Thu May 08, 11:31AM CDT
Today, Analysts Review released its analysts' notes regarding Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2188-100free.
$1.125 billion sale of Vertex Pharmaceuticals headquarters in Boston by HFF
Thomson Reuters ONE - Wed May 07, 10:17PM CDT
BOSTON, MA - May 7, 2014 - HFF announced today that it has closed the sale of the Vertex Pharmaceuticals Incorporated global headquarters, a two-building, state-of-the-art property on Boston's Fan Pier.
William Young Joins Vertex Board of Directors
Business Wire - Wed May 07, 3:06PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that William Young joined its board of directors as an independent director. Mr. Young was elected to the class of directors whose term expires in 2017. The Vertex board now consists of 10 members.
Huntington's Disease - Pipeline Review, H1 2014: 50 Company and 93 Drug Profiles
M2 - Wed May 07, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v2bgc4/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - GAcadia Pharmaceuticals Inc. - Accera, Inc. - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Aniona ApS - Auspex Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Centre de Regulacio Genomica - Chronos Therapeutics Limited - Cortex Pharmaceuticals, Inc. - CrystalGenomics, Inc. - EncephRx, Inc. - Evotec AG - GW Pharmaceuticals plc - Galenea Corp. - Suven Life Sciences Ltd. - Teva Pharmaceutical Industries Limited - Treventis Corporation - Trophos SA - UniQure BV - Valens Therapeutics, Inc. - Varinel, Inc. - Vertex Pharmaceuticals Incorporated - VivaCell Biotechnology Espana S.L. - Vybion, Inc. - Wellstat Therapeutics Corporation - enzyme Corporation - iPierian, Inc Drug Profiles: - pridopidine - SD-809 ER - Coenzyme Q10 - cysteamine DR - PF-02545920 - nabiximols - selisistat - PBT-2 - Epigallocatechin Gallate - BN-82451 - SOM-3355 - OMS-824 - SRX-251 - SRX-246 - SUVN-502 - GSK-356278 - uridine triacetate - Lithium citrate - ALN-HTT - CERE-120 - INDUS-815C - AC-0523 - Xpro-1595 - AN-726 - CX-929 - VAR-10300 - AMT-090 - noscapine - NsG-33 - MTP-131 For more information visit http://www.researchandmarkets.com/research/v2...untingtons
Stock Market News for May 07, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed May 07, 9:06AM CDT
Selling pressure in Internet stocks and a decline in AIG’s quarterly income dragged the benchmarks down on Tuesday
Epilepsy - Pipeline Review, H1 2014: 43 Companies and 97 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/652dzz/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aestus Therapeutics, Inc. - Allergan, Inc. - Anavex Life Sciences Corp. - Aniona ApS - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - Bio-Link Australia Pty. Ltd. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Celentyx Ltd. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - GW Pharmaceuticals plc - Glialogix, Inc. - Sun Pharmaceutical Industries Limited - UCB S.A. - Upsher-Smith Laboratories, Inc. - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. - XERIS Pharmaceuticals, Inc. - Zalicus Inc. Drug Profiles: - lacosamide - perampanel - eslicarbazepine acetate - diazepam - ADV-5803 - lacosamide - brivaracetam - carbamazepine - carisbamate - diazepam - eslicarbazepine acetate - lacosamide - everolimus - belnacasan - YKP-3089 - naluzotan - DP-VPA - selurampanel - ganaxolone - IPX-218 - topiramate - tonabersat - GWP-42006 - SUN-44 - INS-001 - PF-04895162 - CKD-903 - ANAVEX-2-73 - Antiepileptic Drugs - ANAVEX-19-144 For more information visit http://www.researchandmarkets.com/research/652dzz/epilepsy
Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 07, 8:34AM CDT
Several companies reported earnings and provided regulatory and pipeline updates last week.
Prestigious Recognitions, Product Enhancements, and Earnings Releases - Analyst Notes on Discover, BlackRock, Covance, BioMarin and Vertex
PR Newswire - Wed May 07, 7:29AM CDT
Today, Analysts Review released its analysts' notes regarding Discover Financial Services (NYSE: DFS), BlackRock, Inc. (NYSE: BLK), Covance Inc. (NYSE: CVD), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2142-100free.
Pre-market Biotech Picks -- Research on Dendreon, Keryx Biopharma, Idera Pharma, and Vertex Pharma
PR Newswire - Wed May 07, 7:00AM CDT
The US markets saw a negative sentiment on Tuesday, May 6, 2014, with the NASDAQ Composite closing at 4,080.76, down 1.38%, the Dow Jones Industrial Average ending the session 0.78% lower at 16,401.02, and the S&P 500 edging 0.90% lower to finish the trading session at 1,867.72. The loss were broad based with nine out of the ten sectors finishing lower. The S&P 500 Health Care Sector Index ended the day at 666.48, down 0.91%, whereas the index has gained 4.08% in the previous three months. Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Idera Pharmaceuticals Inc. (NASDAQ: IDRA) and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free technical research on DNDN, KERX, IDRA and VRTX can be downloaded upon signing up at:
Vertex Pharmaceuticals, Inc.'s (VRTX) CEO Jeffrey Leiden on Q1 2014 Earnings - Call Transcript
at The Street - Tue May 06, 5:55AM CDT
Vertex Pharmaceuticals, Inc. (VRTX) Q1 2014 Earnings Call Corrected Transcript: 01-May-2014
Vertex Down on Wider-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 10:20AM CDT
Vertex Pharmaceuticals Inc. (VRTX) reported first quarter 2014 loss of 85 cents per share (including stock-based compensation expense).
Why Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals, Inc., and F5 Networks, Inc. Are To
John Divine, The Motley Fool - Motley Fool - Fri May 02, 6:42PM CDT
Wall Street, anxiously awaiting Friday's jobs report for the last several days, finally got the news it was waiting for today. But the monthly employment snapshot, instead of providing a nice, clean-cut, crystal-clear data set for investors to make...
For The Record
at Investor's Business Daily - Fri May 02, 5:58PM CDT
For The Record: In a May 2 news item on Vertex Pharmaceuticals (VRTX), IBD should have stated that the drugmaker reported positive results from a Phase 2 trial.
Vertex Pharmaceuticals
at Investor's Business Daily - Thu May 01, 5:54PM CDT
Vertex Pharmaceuticals (VRTX) late Thu. reported a smaller-than-expected Q1 adjusted loss of 65 cents a share. It also said an experimental drug combined with its Kalydeco significantly improved lung function for a certain type of cystic fibrosis in...
Vertex's Sales Plunge 64% as It Refocuses Its Pipeline on Cystic Fibrosis Therapies
Sean Williams, The Motley Fool - Motley Fool - Thu May 01, 4:46PM CDT
Large-cap biopharmaceutical company Vertex Pharmaceuticals is right in the middle of a product transition from a dual focus on hepatitis C and cystic fibrosis to a full focus on cystic fibrosis – and its first-quarter results demonstrate those...
Addition of VX-661 to KALYDECO(R) (ivacaftor) Improves Lung Function in People with CF Who Are Heterozygous for the F508del and G551D Mutations in 28-day Phase 2 Proof-of-Concept Study
Business Wire - Thu May 01, 3:02PM CDT
---Statistically significant improvements in lung function, as well as decreases in sweat chloride, observed through 28 days of treatment with VX-661 and KALYDECO-
Vertex Reports First Quarter 2014 Financial Results and Provides Updates on Key Business Priorities
Business Wire - Thu May 01, 3:02PM CDT
---Cash, cash equivalents and marketable securities of $1.32 billion on March 31, 2014-
Why You Should Watch Exelixis Inc., Geron Corporation and Vertex Pharmaceuticals Today
George Budwell, The Motley Fool - Motley Fool - Thu May 01, 8:01AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Exelixis , Geron , and Vertex Pharmaceuticals today. Exelixis set to release first quarter results today Normally, earnings season for...
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Stock Market News for April 30, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 9:06AM CDT
Upbeat earnings results and gains in high-growth stocks helped benchmarks close in the green on Tuesday
Healthcare Companies Report Studies, Financial Results, and Upcoming Conferences - Analyst Notes on Vertex, PerkinElmer, PAREXEL, ACADIA Pharmaceuticals and Arena Pharmaceuticals
PR Newswire - Thu May 08, 11:31AM CDT
Today, Analysts Review released its analysts' notes regarding Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2188-100free.
$1.125 billion sale of Vertex Pharmaceuticals headquarters in Boston by HFF
Thomson Reuters ONE - Wed May 07, 10:17PM CDT
BOSTON, MA - May 7, 2014 - HFF announced today that it has closed the sale of the Vertex Pharmaceuticals Incorporated global headquarters, a two-building, state-of-the-art property on Boston's Fan Pier.
William Young Joins Vertex Board of Directors
Business Wire - Wed May 07, 3:06PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that William Young joined its board of directors as an independent director. Mr. Young was elected to the class of directors whose term expires in 2017. The Vertex board now consists of 10 members.
Huntington's Disease - Pipeline Review, H1 2014: 50 Company and 93 Drug Profiles
M2 - Wed May 07, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v2bgc4/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - GAcadia Pharmaceuticals Inc. - Accera, Inc. - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Aniona ApS - Auspex Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Centre de Regulacio Genomica - Chronos Therapeutics Limited - Cortex Pharmaceuticals, Inc. - CrystalGenomics, Inc. - EncephRx, Inc. - Evotec AG - GW Pharmaceuticals plc - Galenea Corp. - Suven Life Sciences Ltd. - Teva Pharmaceutical Industries Limited - Treventis Corporation - Trophos SA - UniQure BV - Valens Therapeutics, Inc. - Varinel, Inc. - Vertex Pharmaceuticals Incorporated - VivaCell Biotechnology Espana S.L. - Vybion, Inc. - Wellstat Therapeutics Corporation - enzyme Corporation - iPierian, Inc Drug Profiles: - pridopidine - SD-809 ER - Coenzyme Q10 - cysteamine DR - PF-02545920 - nabiximols - selisistat - PBT-2 - Epigallocatechin Gallate - BN-82451 - SOM-3355 - OMS-824 - SRX-251 - SRX-246 - SUVN-502 - GSK-356278 - uridine triacetate - Lithium citrate - ALN-HTT - CERE-120 - INDUS-815C - AC-0523 - Xpro-1595 - AN-726 - CX-929 - VAR-10300 - AMT-090 - noscapine - NsG-33 - MTP-131 For more information visit http://www.researchandmarkets.com/research/v2...untingtons
Stock Market News for May 07, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed May 07, 9:06AM CDT
Selling pressure in Internet stocks and a decline in AIG’s quarterly income dragged the benchmarks down on Tuesday
Epilepsy - Pipeline Review, H1 2014: 43 Companies and 97 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/652dzz/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aestus Therapeutics, Inc. - Allergan, Inc. - Anavex Life Sciences Corp. - Aniona ApS - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - Bio-Link Australia Pty. Ltd. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Celentyx Ltd. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - GW Pharmaceuticals plc - Glialogix, Inc. - Sun Pharmaceutical Industries Limited - UCB S.A. - Upsher-Smith Laboratories, Inc. - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. - XERIS Pharmaceuticals, Inc. - Zalicus Inc. Drug Profiles: - lacosamide - perampanel - eslicarbazepine acetate - diazepam - ADV-5803 - lacosamide - brivaracetam - carbamazepine - carisbamate - diazepam - eslicarbazepine acetate - lacosamide - everolimus - belnacasan - YKP-3089 - naluzotan - DP-VPA - selurampanel - ganaxolone - IPX-218 - topiramate - tonabersat - GWP-42006 - SUN-44 - INS-001 - PF-04895162 - CKD-903 - ANAVEX-2-73 - Antiepileptic Drugs - ANAVEX-19-144 For more information visit http://www.researchandmarkets.com/research/652dzz/epilepsy
Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 07, 8:34AM CDT
Several companies reported earnings and provided regulatory and pipeline updates last week.
Prestigious Recognitions, Product Enhancements, and Earnings Releases - Analyst Notes on Discover, BlackRock, Covance, BioMarin and Vertex
PR Newswire - Wed May 07, 7:29AM CDT
Today, Analysts Review released its analysts' notes regarding Discover Financial Services (NYSE: DFS), BlackRock, Inc. (NYSE: BLK), Covance Inc. (NYSE: CVD), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2142-100free.
Pre-market Biotech Picks -- Research on Dendreon, Keryx Biopharma, Idera Pharma, and Vertex Pharma
PR Newswire - Wed May 07, 7:00AM CDT
The US markets saw a negative sentiment on Tuesday, May 6, 2014, with the NASDAQ Composite closing at 4,080.76, down 1.38%, the Dow Jones Industrial Average ending the session 0.78% lower at 16,401.02, and the S&P 500 edging 0.90% lower to finish the trading session at 1,867.72. The loss were broad based with nine out of the ten sectors finishing lower. The S&P 500 Health Care Sector Index ended the day at 666.48, down 0.91%, whereas the index has gained 4.08% in the previous three months. Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Idera Pharmaceuticals Inc. (NASDAQ: IDRA) and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free technical research on DNDN, KERX, IDRA and VRTX can be downloaded upon signing up at:
Vertex Pharmaceuticals, Inc.'s (VRTX) CEO Jeffrey Leiden on Q1 2014 Earnings - Call Transcript
at The Street - Tue May 06, 5:55AM CDT
Vertex Pharmaceuticals, Inc. (VRTX) Q1 2014 Earnings Call Corrected Transcript: 01-May-2014
Vertex Down on Wider-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 10:20AM CDT
Vertex Pharmaceuticals Inc. (VRTX) reported first quarter 2014 loss of 85 cents per share (including stock-based compensation expense).
Why Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals, Inc., and F5 Networks, Inc. Are To
John Divine, The Motley Fool - Motley Fool - Fri May 02, 6:42PM CDT
Wall Street, anxiously awaiting Friday's jobs report for the last several days, finally got the news it was waiting for today. But the monthly employment snapshot, instead of providing a nice, clean-cut, crystal-clear data set for investors to make...
For The Record
at Investor's Business Daily - Fri May 02, 5:58PM CDT
For The Record: In a May 2 news item on Vertex Pharmaceuticals (VRTX), IBD should have stated that the drugmaker reported positive results from a Phase 2 trial.
Vertex Pharmaceuticals
at Investor's Business Daily - Thu May 01, 5:54PM CDT
Vertex Pharmaceuticals (VRTX) late Thu. reported a smaller-than-expected Q1 adjusted loss of 65 cents a share. It also said an experimental drug combined with its Kalydeco significantly improved lung function for a certain type of cystic fibrosis in...
Vertex's Sales Plunge 64% as It Refocuses Its Pipeline on Cystic Fibrosis Therapies
Sean Williams, The Motley Fool - Motley Fool - Thu May 01, 4:46PM CDT
Large-cap biopharmaceutical company Vertex Pharmaceuticals is right in the middle of a product transition from a dual focus on hepatitis C and cystic fibrosis to a full focus on cystic fibrosis – and its first-quarter results demonstrate those...
Addition of VX-661 to KALYDECO(R) (ivacaftor) Improves Lung Function in People with CF Who Are Heterozygous for the F508del and G551D Mutations in 28-day Phase 2 Proof-of-Concept Study
Business Wire - Thu May 01, 3:02PM CDT
---Statistically significant improvements in lung function, as well as decreases in sweat chloride, observed through 28 days of treatment with VX-661 and KALYDECO-
Vertex Reports First Quarter 2014 Financial Results and Provides Updates on Key Business Priorities
Business Wire - Thu May 01, 3:02PM CDT
---Cash, cash equivalents and marketable securities of $1.32 billion on March 31, 2014-
Why You Should Watch Exelixis Inc., Geron Corporation and Vertex Pharmaceuticals Today
George Budwell, The Motley Fool - Motley Fool - Thu May 01, 8:01AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Exelixis , Geron , and Vertex Pharmaceuticals today. Exelixis set to release first quarter results today Normally, earnings season for...
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Stock Market News for April 30, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 9:06AM CDT
Upbeat earnings results and gains in high-growth stocks helped benchmarks close in the green on Tuesday
